Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Fetcroja (cefiderocol) is a siderophore cephalosporin antibiotic designed to treat serious infections caused by difficult-to-treat aerobic Gram-negative bacteria, including certain carbapenem-resistant organisms. Fetcroja is the EU/international brand name; the same active ingredient is marketed in the United States as Fetroja.
Fetcroja is approved for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options, reserved for cases where other antibiotic options are inadequate.
Cefiderocol uses a unique "Trojan horse" mechanism, binding iron and using the bacteria's own iron-transport channels to cross the outer bacterial membrane, then inhibiting cell wall synthesis like other cephalosporin antibiotics — allowing it to overcome many resistance mechanisms that block conventional antibiotics.
The standard dose is 2 g administered by intravenous infusion over 3 hours, every 8 hours, with dose adjustment for renal function, as determined by the treating infectious disease specialist.
Important Safety Information — Fetcroja: Clinical trial data (the CREDIBLE-CR study) showed an increase in all-cause mortality in cefiderocol-treated patients compared to those on best available therapy, observed primarily in patients with carbapenem-resistant infections. Fetcroja should be reserved for use in patients with limited or no alternative treatment options, and used only after careful assessment of benefits and risks by the treating physician.
Use only when the benefits are judged to outweigh the risks, particularly in critically ill patients with limited alternative options.
Serious hypersensitivity reactions can occur, including in patients with known beta-lactam allergy.
Can occur during or after treatment. Evaluate if diarrhea develops.
Central nervous system reactions, including seizures, have been reported, particularly with renal impairment and inappropriate dosing.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Fetcroja (cefiderocol) is manufactured by Shionogi. Fetcroja is the EU/international brand name; the same active ingredient is marketed in the United States as Fetroja.
Import of Fetcroja through a Named Patient Program requires a valid prescription from the treating infectious disease specialist, confirmation of infection type and prior treatment history, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Fetcroja directly from Shionogi's authorized supply chain to ensure product authenticity and regulatory compliance.
Fetcroja is sourced through verified, GDP-compliant, cold-chain channels from Shionogi's authorized supply chain to ensure authenticity and quality.
Fetcroja vials should be stored refrigerated at 2°C to 8°C, protected from light, and kept in the original carton until time of use.
Once sourced, Fetcroja is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Fetcroja through NPP's regulated import pathway, with infectious disease and critical care specialists in major cities supporting the treatment process.
Leading infectious disease centers in Mumbai support treatment coordination for Fetcroja access.
Delhi's major hospitals assist patients with prescription support and documentation for Fetcroja.
Bangalore's specialist network offers access to Fetcroja for patients with limited treatment options.
Chennai-based specialists coordinate Fetcroja access alongside comprehensive infection management.
Hyderabad's care institutions support patients pursuing Fetcroja therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Fetcroja.
Pune-based specialists assist with treatment planning for Fetcroja.
Ahmedabad's specialty hospitals support the import and treatment process for Fetcroja.
Kochi's specialist units assist patients with the documentation needed for Fetcroja access.
Chandigarh's care centers support Fetcroja treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Fetcroja access process.
Lucknow-based centers assist patients pursuing Fetcroja therapy.
Bhubaneswar's institutions support access to Fetcroja for eligible patients.
Guwahati's specialists help coordinate Fetcroja access for patients across the Northeast.
Patients in other cities across India can also access Fetcroja through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
